title: Alzheimer's drugs take a new tack.
authors.forename: Ewen
authors.initials: E
authors.lastname: Callaway
mesh_terms: D000328:Adult; D017668:Age of Onset; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods*; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D006801:Humans; D038622:Internationality; D008875:Middle Aged; D013997:Time Factors
chemical_list: D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; C550616:solanezumab; C545458:bapineuzumab; C573372:crenezumab